|
1
|
Sauer R, Becker H, Hohenberger W, et al:
Preoperative versus postoperative chemoradiotherapy for rectal
cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bosset JF, Calais G, Mineur L, et al:
Enhanced tumoricidal effect of chemotherapy with preoperative
radiotherapy for rectal cancer: preliminary results-EORTC 22921. J
Clin Oncol. 23:5620–5627. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bosset JF, Collette L, Calais G, et al:
Chemotherapy with preoperative radiotherapy in rectal cancer. N
Engl J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gerard J, Romestaing P, Bonnetain F, et
al: Preoperative chemoradiotherapy (CT-RT) improves local control
in T3-4 rectal cancers: results of the FFCD 9203 randomised trial.
Int J Radiat Oncol Biol Phys. 63:2–3. 2005. View Article : Google Scholar
|
|
5
|
Das P and Crane CH: Preoperative and
adjuvant treatment of localized rectal cancer. Curr Oncol Rep.
8:167–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McLean CM and Duncan W: Rectal cancer: a
review of randomized trials of adjuvant radiotherapy. Clin Oncol.
7:349–358. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedmann P, Garb JL, Park WC, et al: Pace
OT survival following moderate-dose preoperative radiation therapy
for carcinoma of the rectum. Cancer. 55:967–973. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kerman HD, Roberson SH, Bloom TS, et al:
Rectal carcinoma. Long-term experience with moderately high-dose
preoperative radiation and low anterior resection. Cancer.
69:2813–2819. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim DW, Lim SB, Kim DY, et al:
Pre-operative chemo-radiotherapy improves the sphincter
preservation rate in patients with rectal cancer located within 3
cm of the anal verge. Eur J Surg Oncol. 32:162–167. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Minsky BD: Oxaliplatin-based
combined-modality therapy for rectal cancer. Semin Oncol. 30:26–33.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Du C, Fang M, Li Y, Li L and Wang X: Smac,
a mitochondrial protein that promotes cytochrome c dependent
caspase activation by elimination IAP inhibition. Cell. 102:33–42.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang S-M, Maeda K, Onoda N, et al:
Combined analysis of p53 and vascular endothelial growth factor in
CRC for determination of tumor vascularity and liver metastasis.
Int J Cancer. 74:502–507. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wong MP, Cheung N, Yuen ST, Leung SY and
Chung LP: Vascular endothelial GF is up-regulated in the early
pre-malignant stage of colorectal tumor progression. Int J Cancer.
81:845–850. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tonini T, Rossi F and Claudio PP:
Molecular basis of angiogenesis and cancer. Oncogene. 22:6549–6556.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lutsenko SV, Kiselev SM and Severin SE:
Molecular mechanisms of tumor angiogenesis. Biochem. 68:286–300.
2003.
|
|
16
|
Ferrara N, Gerber H-P and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Falm E: Angiogenesis inhibitors in
clinical development; where are we now and where are we going? Br J
Cancer. 90:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ferrara N: Vascular endothelial growth
factor: basic science and clinical progress. Endocr Rev.
25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Harmey JH and Bouchier-Hayes D: Vascular
endothelial growth factor (VEGF), a survival factor for tumour
cells: implications for anti-angiogenic therapy. Bioessays.
24:280–283. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Willett C, Boucher Y, di Tomaso E, et al:
Direct evidence that the VEGF-specific antibody bevacizumab has
anti-vascular effects in human rectal cancer. Nat Med. 10:145–147.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gerdes J, Lemke H, Baisch H, Wacker HH,
Schwab U and Stein H: Cell cycle analysis of a cell
proliferation-associated human nuclear antigen defined by the
monoclonal antibody Ki-67. J Immunol. 133:1710–1715.
1984.PubMed/NCBI
|
|
22
|
Song Z, Yao X and Wu M: Direct interaction
between survivin and Smac/DIABLO is essential for the
anti-apoptotic activity of survivin during taxol-induced apoptosis.
J Biol Chem. 278:23130–23140. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roberts DL, Merrison W, MacFarlane M and
Cohen GM: The inhibitor of apoptosis protein-binding domain of Smac
is not essential for its proapoptotic activity. J Cell Biol.
153:221–228. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sekimura A, Konishi A, Mizuno K, et al:
Expression of Smac/DIABLO is a novel prognostic marker in lung
cancer. Oncol Rep. 11:797–802. 2004.PubMed/NCBI
|
|
25
|
Zheng LD, Xiong ZF, Zhu JW and Wang ZH:
Effects of Smac gene over-expression on the radiotherapeutic
sensitivities of cervical cancer cell line HeLa [J]. Chin Med J.
118:226–230. 2005.PubMed/NCBI
|
|
26
|
Jia L, Patwari Y, Kelsey SM, et al: Role
of Smac in human leukaemic cell apoptosis and proliferation.
Oncogene. 22:1589. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zlobec I, Steele R and Compton CC: VEGF as
a predictive marker of rectal tumor response to preoperative
radiotherapy. Cancer. 104:2517–2521. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Giralt J, Navalpotro B, Hermosilla E, et
al: Prognostic significance of vascular endothelial growth factor
and cyclooxygenase-2 in patients with rectal cancer treated with
preoperative radiotherapy. Oncology. 71:312–319. 2006. View Article : Google Scholar
|
|
29
|
Kakeji Y, Koga T, Sumiyoshi Y, et al:
Clinical significance of vascular endothelial growth factor
expression in gastric cancer. J Exp Clin Cancer Res. 21:125–129.
2002.PubMed/NCBI
|
|
30
|
Inoue Y, Ojima E, Watanabe H, et al: Does
preoperative chemo-radiotherapy enhance the expression of vascular
endothelial growth factor in patients with rectal cancer? Oncol
Rep. 18:369–375. 2007.PubMed/NCBI
|
|
31
|
Rau B, Sturm I, Lage H, et al: Dynamic
expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in
rectal carcinoma treated with preoperative radiochemotherapy. J
Clin Oncol. 21:3391–3401. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim NK, Park JK, Lee KY, et al: p53, BCL-2
and Ki-67 expression according to tumor response after concurrent
chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol.
8:418–424. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Scholzen T and Gerdes J: The Ki-67
protein: from the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Adell G, Zhang H, Jansson A, Sun XF, Stål
O and Nordenskjöld B: Decreased tumor cell proliferation as an
indicator of the effect of preoperative radiotherapy of rectal
cancer. Int J Radiat Oncol Biol Phys. 50:659–663. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Debucquoy A, Goethals L, Geboes K, Roels
S, Mc Bride WH and Haustermans K: Molecular responses of rectal
cancer to preoperative chemoradiation. Radiother Oncol. 80:172–177.
2006. View Article : Google Scholar : PubMed/NCBI
|
